1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Commissioner Nominee's Required Divestitures Illustrate US FDA's Broader Recruitment Challenge

 
• By Derrick Gingery

Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.

FDABldg1ExteriorWithCircle_1200x675
Stephen Hahn also pledged to give up potential patent royalties should he be confirmed as FDA commissioner. • Source: File photo

Stephen Hahn's financial disclosure and ethics agreements provide another example of the US Food and Drug Administration's difficulties recruiting external candidates for senior leadership positions.

Hahn pledged to divest 132 stocks he owned should he be confirmed as FDA commissioner, which are worth between $356,132...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

More from Agency Leadership